Galenvs Sciences Inc.: federal grants and contributions: 8 agreements; $2.4M value; 2 departments; 5 programs.
Assay record ASY-CA-10ZVAYS1II · Cite as: Assay Systems, “Galenvs Sciences Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/galenvs-sciences-inc/
Not a Project (Mandated or Core Funding)
The Firm seeks to advance the state of the art in aptamer drug development through the development of novel chemistries of non-natural or modified natural nucleotides and synthesis and purification methods for a large DNA-encoded aptamer library. The technology will leverage core expertise in the design and manufacturing of magnetic nanoparticles and in-house large-scale high-purity synthesis of oligonucleotide services to provide the biopharmaceutical and biotechnology industry with products and services that will accelerate the design and screening of aptamers for therapeutic drug discovery
As part of the international consortium project “GREEN-MNP-BUFFER," this project will focus on developing next-generation magnetic nanoparticle and buffer formulations using proprietary, sustainable, and biodegradable chemistries.
COVID-19 Challenge: To develop a proof of concept for The National Research Council Canada (NRC) is seeking a solution for reagents required for nucleic acid sample preparation and rapid and efficient SARS-CoV-2 Ribonucleic Acid (RNA) extraction in order to perform downstream molecular diagnostics of COVID-19 with capability to integrate within existing and/or potential microfluidic platforms for sample-to-answer solutions that can be deployed on the frontline for rapid testing.
Not a Project (Mandated or Core Funding)
As part of Multinational Corporate Collaboration Program, the project “Development of Functionalized MNPs and Oligonucleotides for Purification and Diagnostics” will focus on advancing technologies for improved diagnostics and higher yields and purity of oligos/nucleic acids
The firm is advancing the development of rapid diagnostic workflows for detecting Haplosporidium nelsoni in oysters, leveraging its expertise in sample preparation using magnetic nanoparticles and specialized buffer formulations. The project focuses on the efficient extraction of genomic material, the design of sensitive PCR and isothermal detection systems, and the production of high-purity oligonucleotide probes and primers. With ISO 9001-certified manufacturing capabilities, the firm is well-positioned to commercialize these diagnostic tools, enhancing pathogen detection and supporting the
The youth will join the firm's’ oligonucleotide synthesis team to support the development, evaluation, production, and delivery of chemically-modified aptamer sequences and other oligonucleotide therapeutic candidates for the firm's clients.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.